Valantine Hannah 4

4 · BridgeBio Pharma, Inc. · Filed Jun 24, 2026

AI-generated summary of this filing

Updated Jun 24, 2026

BridgeBio (BBIO) Director Hannah Valantine Sells Shares After Exercising Options

What Happened

Director Hannah Valantine exercised stock options to acquire 2,808 shares on 2026-06-22 at $41.73/share (cost $117,178) and sold those 2,808 shares the same day in an open-market sale at $68.00/share (proceeds $190,944). She sold an additional 2,196 shares on 2026-06-23 at $68.57/share (proceeds $150,580). Total sale proceeds = $341,524; net cash after the option exercise (proceeds minus exercise cost) ≈ $224,346.
The filing also reports awards: 3,990 restricted stock units (RSUs) and a derivative award covering 5,277 underlying shares (see Key Details for vesting).

Key Details

Transaction dates & prices:
- 2026-06-22: Exercised 2,808 options @ $41.73 (acquired) — $117,178.
- 2026-06-22: Sold 2,808 shares @ $68.00 — $190,944.
- 2026-06-23: Sold 2,196 shares @ $68.57 — $150,580.
- Grants reported: 3,990 RSUs and a 5,277-share derivative award (both reported at $0 acquisition price).
Shares sold total: 5,004 shares for $341,524 in aggregate.
Shares owned after the transactions: Not specified in this filing.
Footnotes of note:
- RSUs: Each RSU converts to one share; the 3,990 RSUs vest in full on June 22, 2027, subject to continued board service (F1, F2).
- Option/derivative vesting: The option-related award underlying 5,277 shares has multi-year vesting (one-third per year after June 20, 2025, with full vesting by June 20, 2028; another note shows vesting in full by June 22, 2027) — see F4–F5 for details.
- One or more sales were executed pursuant to a Rule 10b5-1 trading plan adopted Nov 14, 2025 (F3).
Timeliness: The Form 4 was filed on 2026-06-24 reporting transactions from 2026-06-22 — the filing appears timely (within the two business-day reporting window).

Context

This was an exercise of options followed by immediate open-market sales of the resulting shares (a common way to cover exercise costs and realize gains). One sale was executed under a pre-set 10b5-1 plan, which typically indicates trades were prearranged rather than timed to new material information.
Grants of RSUs and multi-year-vesting options do not represent immediate stock ownership until vested; they are retention/compensation awards subject to service-based vesting conditions.

Form 4

Period: 2026-06-22

Director

Transactions

Award
Common Stock
[F1][F2]
2026-06-22+3,990→ 11,455 total
Exercise/Conversion
Common Stock
2026-06-22$41.73/sh+2,808$117,178→ 14,263 total
Sale
Common Stock
[F3]
2026-06-22$68.00/sh−2,808$190,944→ 11,455 total
Sale
Common Stock
[F3]
2026-06-23$68.57/sh−2,196$150,580→ 9,259 total
Award
Stock Option (Right to Buy)
[F4]
2026-06-22+5,277→ 5,277 total
Exercise: $68.92Exp: 2036-06-21→ Common Stock (5,277 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F5]
2026-06-22−2,808→ 5,617 total
Exercise: $41.73Exp: 2035-06-19→ Common Stock (2,808 underlying)

Holdings

Footnotes (5)

[F1]Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
[F4]The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
[F5]One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

Signature

/s/ Will Solis, Attorney-in-Fact|2026-06-24

1 file